Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.

BACKGROUND The pathogenesis of substantia nigra pars compacta neuronal injury in Parkinson disease (PD) remains unknown. Cerebrospinal fluid (CSF) has been reported to contain factors toxic to dopaminergic neurons. OBJECTIVES To determine whether the cytotoxic effects of CSF of PD patients are specific for dopaminergic neurons, dependent on prior levodopa therapy, and mediated by the cytokine tumor necrosis factor alpha (TNF-alpha). DESIGN Specimens of CSF were evaluated in dopaminergic (MES 23.5) and nondopaminergic (N18TG2) cell lines for cytotoxicity by viability assay and by the inhibition of tyrosine hydroxylase. After specificity and time and dose response were established, CSF specimens were assayed in a blinded manner. The TNF-alpha levels in CSF were determined by enzyme-linked immunosorbent assay. The toxicity of TNF-alpha in MES 23.5 cells was determined. SETTING A university-based research facility. SUBJECTS There were 4 groups of subjects: normal control subjects (n = 10), control subjects with neurologic disease (n = 8), PD patients treated with levodopa (n = 10), and untreated subjects with PD (n= 20). RESULTS Specimens of CSF from 15 (50%) of 30 PD patients and 2 (11%) of 18 control subjects were cytotoxic to dopaminergic MES 23.5 cells and were nontoxic to the parental cell line N18TG2. There was no correlation between the degree of PD CSF cytotoxicity, levodopa therapy, or the severity and duration of PD. Terminal deoxynucleotidyl transferase-mediated biotin-deoxyuridine triphosphate nick-end labeling (TUNEL) for DNA fragmentation suggested the involvement of apoptotic mechanisms. The inhibition of tyrosine hydroxylase was an early effect of cell injury by PD CSF and correlated with the viability assay. The mean TNF-alpha level was 2.6-fold higher in CSF specimens from PD patients than in those of controls. The addition of recombinant human TNF-alpha equivalent to the highest level determined in PD CSF was not cytotoxic to MES 23.5 cultures. CONCLUSIONS Blinded CSF specimens from PD patients, regardless of therapy, contain factors that cause specific dopaminergic neuronal cell injury. These factors are present in a substantial proportion of CSF specimens from patients with early PD, before the institution of medical therapy. Levels of TNF-alpha are elevated in the CSF of PD patients, but TNF-alpha is not responsible for the cytotoxicity.

[1]  M. Mattson,et al.  Presence of 4‐hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis , 1998, Annals of neurology.

[2]  S. Appel,et al.  Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. , 1998, Archives of neurology.

[3]  W. D. Ehmann,et al.  Elevated 4-Hydroxynonenal in Ventricular Fluid in Alzheimer’s Disease , 1997, Neurobiology of Aging.

[4]  D. Wallach,et al.  Cell death induction by TNF: a matter of self control. , 1997, Trends in biochemical sciences.

[5]  G. Kreutzberg Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[6]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[8]  L. Colom,et al.  Cell death induced by β-amyloid 1–40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis , 1995, Brain Research.

[9]  S. Appel,et al.  Experimental autoimmune nigral damage in guinea pigs , 1995, Journal of Neuroimmunology.

[10]  R. Norgren,et al.  Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture , 1995, Neurology.

[11]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[12]  C. Marsden,et al.  New insights into the cause of Parkinson's disease , 1992, Neurology.

[13]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[14]  J. Tajti,et al.  Nigral damage and dopaminergic hypofunction in mesencephalon‐immunized guinea pigs , 1992, Annals of neurology.

[15]  E. Stefani,et al.  A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  C. Olanow Oxidation reactions in Parkinson's disease , 1990, Neurology.

[17]  Olanow Cw Oxidation reactions in Parkinson's disease. , 1990 .

[18]  C. Tanner,et al.  The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.

[19]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[20]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[21]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[22]  M. Naoi,et al.  N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. , 1997, Journal of neural transmission. Supplementum.

[23]  P Riederer,et al.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.

[24]  P. Riederer,et al.  Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.

[25]  J. Bostwick,et al.  A tyrosine hydroxylase assay in microwells using coupled nonenzymatic decarboxylation of dopa. , 1991, Analytical biochemistry.

[26]  A. Dahlström,et al.  Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. , 1990, Journal of neural transmission. Supplementum.